DNA vaccine for Japanese encephalitis virus
    1.
    发明申请
    DNA vaccine for Japanese encephalitis virus 审中-公开
    日本脑炎病毒DNA疫苗

    公开(公告)号:US20070190617A1

    公开(公告)日:2007-08-16

    申请号:US11353212

    申请日:2006-02-13

    IPC分类号: C12Q1/68 C12P19/34

    摘要: A DNA vaccine of Japanese encephalitis virus (JEV) of the present invention comprises at least one vector encoding a membrane protein and an envelope protein gene of JEV. Furthermore, the DNA vaccine contains a cytomegalovirus early promoter sequence, an enhancer sequence, a chimeric intron, a bovine growth hormone polyadenylation sequence and a kanamycin resistant gene. The DNA vaccine can enhance antigentic stability and provide a high level of immunity.

    摘要翻译: 本发明的日本脑炎病毒(JEV)的DNA疫苗包含编码JEV的膜蛋白和包膜蛋白基因的至少一种载体。 此外,DNA疫苗含有巨细胞病毒早期启动子序列,增强子序列,嵌合内含子,牛生长激素多聚腺苷酸化序列和卡那霉素抗性基因。 DNA疫苗可以增强抗病毒稳定性并提供高水平的免疫力。

    THERMOSENSITIVE HEPATITIS B VACCINE
    2.
    发明申请
    THERMOSENSITIVE HEPATITIS B VACCINE 审中-公开
    感冒性乙型肝炎疫苗

    公开(公告)号:US20120045511A1

    公开(公告)日:2012-02-23

    申请号:US12858305

    申请日:2010-08-17

    IPC分类号: A61K9/00 A61K39/29

    摘要: A thermosensitive hepatitis B vaccine is provided. The thermosensitive hepatitis B vaccine includes an aqueous phase solution comprising a biodegradable thermosensitive hydrogel copolymer; a surface antigen of hepatitis B virus (HBsAg); and a bioactive substance. The thermosensitive hepatitis B vaccine of the disclosure is particularly suitable for being applied in the patients, which are low responsive or non-responsive to conventional hepatitis B vaccine, for enhancing the induction of cell-mediated immune responses and overcoming the HBsAg non-responsiveness.

    摘要翻译: 提供热敏乙肝疫苗。 热敏乙型肝炎疫苗包括含有可生物降解的热敏水凝胶共聚物的水相溶液; 乙型肝炎病毒(HBsAg)的表面抗原; 和生物活性物质。 本公开的热敏乙型肝炎疫苗特别适合于应用于对常规乙型肝炎疫苗具有低响应性或无反应性的患者,用于增强细胞介导的免疫应答的诱导并克服HBsAg无反应性。

    NON-HUMAN ANIMAL DISEASE MODEL FOR HEPATITIS B VIRUS-ASSOCIATED DISEASE
    3.
    发明申请
    NON-HUMAN ANIMAL DISEASE MODEL FOR HEPATITIS B VIRUS-ASSOCIATED DISEASE 有权
    乙型肝炎病毒相关疾病非人类动物病毒模型

    公开(公告)号:US20110136100A1

    公开(公告)日:2011-06-09

    申请号:US12959632

    申请日:2010-12-03

    摘要: A non-human animal disease model for hepatitis B virus-associated liver disease is disclosed. The animal disease model is transduced with a hepatitis B virus genome in the liver cells thereof and exhibits the following symptoms: hepatitis B viral particles and hepatitis B viral DNA in the serum, hepatitis B virus (HBV) envelope and HBV e proteins in the serum, expression of HBV core and HBV envelope proteins in the liver but not in the kidney, heart, lung, brain, pancreas, spleen, stomach or intestine tissues. The animal disease model may develop hepatocellular carcinoma, exhibiting an elevated level of alanine aminotransferase as compared to a control animal without the hepatitis B virus genome in the liver cells thereof, and liver pathological symptoms such as tumor nodules, dysplasia, inflammatory infiltrates, necrosis and fibrosis.

    摘要翻译: 公开了一种用于乙型肝炎病毒相关肝病的非人动物疾病模型。 动物疾病模型在其肝细胞中用乙型肝炎病毒基因组转导并表现出以下症状:血清中的乙型肝炎病毒颗粒和乙型肝炎病毒DNA,乙型肝炎病毒(HBV)包膜和血清中的HBV e蛋白 ,HBV核心和HBV包膜蛋白在肝脏中表达,但不在肾脏,心脏,肺,脑,胰腺,脾脏,胃或肠组织中表达。 动物疾病模型可能发展为肝细胞癌,与肝细胞中没有乙型肝炎病毒基因组的对照动物相比,表现出高水平的丙氨酸氨基转移酶,以及肝脏病理学症状如肿瘤结节,发育不良,炎性浸润,坏死和 纤维化。

    Enhancement of B cell lymphoma and tumor resistance using
idiotype/cytokine conjugates
    5.
    发明授权
    Enhancement of B cell lymphoma and tumor resistance using idiotype/cytokine conjugates 失效
    使用独特型/细胞因子缀合物增强B细胞淋巴瘤和肿瘤抵抗

    公开(公告)号:US6099846A

    公开(公告)日:2000-08-08

    申请号:US416787

    申请日:1995-04-14

    摘要: B cell lymphoma tumor-associated antigen or a fragment thereof containing an epitope are linked to an immune-enhancing cytokine, such as GM-CSF, IL-2, or IL-4 to form an immuno-complex. This immuno-complex elicits immune responses which are protective with respect to tumor proliferation. The linkers may be simple chemical bifunctional moieties introduced through chemical synthetic techniques or peptides introduce through recombinant methodologies. Antibodies immunoreactive with these immunocomplexes are also useful as passive vaccines and as analytical tools.

    摘要翻译: PCT No.PCT / US93 / 09895 371日期:1995年4月14日 102(e)1995年4月14日PCT PCT 1993年10月14日PCT公布。 公开号WO94 / 08601 日期1994年4月28日B细胞淋巴瘤肿瘤相关抗原或其含有表位的片段与免疫增强细胞因子如GM-CSF,IL-2或IL-4连接以形成免疫复合物。 该免疫复合物引发免疫应答,其对于肿瘤增殖是保护性的。 接头可以是通过化学合成技术引入的简单的化学双功能部分或通过重组方法引入的肽。 与这些免疫复合物免疫反应的抗体也可用作被动疫苗和分析工具。

    Non-human animal disease mode for hepatitis B virus-associated disease
    6.
    发明授权
    Non-human animal disease mode for hepatitis B virus-associated disease 有权
    乙型肝炎病毒相关疾病的非人类动物疾病模式

    公开(公告)号:US08383879B2

    公开(公告)日:2013-02-26

    申请号:US12959632

    申请日:2010-12-03

    IPC分类号: A01K67/00 C12N15/864

    摘要: A non-human animal disease model for hepatitis B virus-associated liver disease is disclosed. The animal disease model is transduced with a hepatitis B virus genome in the liver cells thereof and exhibits the following symptoms: hepatitis B viral particles and hepatitis B viral DNA in the serum, hepatitis B virus (HBV) envelope and HBV e proteins in the serum, expression of HBV core and HBV envelope proteins in the liver but not in the kidney, heart, lung, brain, pancreas, spleen, stomach or intestine tissues. The animal disease model may develop hepatocellular carcinoma, exhibiting an elevated level of alanine aminotransferase as compared to a control animal without the hepatitis B virus genome in the liver cells thereof, and liver pathological symptoms such as tumor nodules, dysplasia, inflammatory infiltrates, necrosis and fibrosis.

    摘要翻译: 公开了一种用于乙型肝炎病毒相关肝病的非人动物疾病模型。 动物疾病模型在其肝细胞中用乙型肝炎病毒基因组转导并表现出以下症状:血清中的乙型肝炎病毒颗粒和乙型肝炎病毒DNA,乙型肝炎病毒(HBV)包膜和血清中的HBV e蛋白 ,HBV核心和HBV包膜蛋白在肝脏中表达,但不在肾脏,心脏,肺,脑,胰腺,脾脏,胃或肠组织中表达。 动物疾病模型可能发展为肝细胞癌,与肝细胞中没有乙型肝炎病毒基因组的对照动物相比,表现出高水平的丙氨酸氨基转移酶,以及肝脏病理学症状如肿瘤结节,发育不良,炎性浸润,坏死和 纤维化。

    Recombinant eukaryotic plasmids containing allergen-gene and use thereof for the prevention and/or treatment of allergic diseases
    7.
    发明授权
    Recombinant eukaryotic plasmids containing allergen-gene and use thereof for the prevention and/or treatment of allergic diseases 失效
    含有过敏原基因的重组真核质粒及其用于预防和/或治疗过敏性疾病的用途

    公开(公告)号:US06251663B1

    公开(公告)日:2001-06-26

    申请号:US09166967

    申请日:1998-10-06

    IPC分类号: A61K3170

    CPC分类号: A61K39/35 A61K2039/53

    摘要: The present invention relates to recombinant eukaryotic plasmids comprising an eukaryotic expression vector and an allergen gene for the prevention and/or treatment of allergic diseases. When the recombinant vector containing allergen-gene administrate to an individual in need of such prevention and/or treatment by intramuscular injection, intranasal delivery or intratracheal delivery, the production of allergen-specific IgE synthesis can be inhibited. The invention also relates to the pharmaceutical compositions comprising the the recombinant vector for use in the the prevention and/or treatment of allergic diseases and the production of allergen-specific IgE synthesis. A method for the prevention and/or treatment of allergic diseases is also provided.

    摘要翻译: 本发明涉及包含真核表达载体和用于预防和/或治疗过敏性疾病的变应原基因的重组真核质粒。 当含有变应原基因的重组载体通过肌内注射,鼻内递送或气管内递送需要这种预防和/或治疗的个体时,可以抑制过敏原特异性IgE合成的产生。 本发明还涉及包含用于预防和/或治疗过敏性疾病和产生变应原特异性IgE合成的重组载体的药物组合物。 还提供了用于预防和/或治疗过敏性疾病的方法。